Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience

Int J Hematol. 2010 Nov;92(4):669-72. doi: 10.1007/s12185-010-0709-3. Epub 2010 Oct 27.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Boronic Acids / administration & dosage
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Dexamethasone / administration & dosage
  • Dexamethasone / therapeutic use
  • Female
  • Graft vs Host Disease / complications
  • Graft vs Host Disease / drug therapy*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / complications
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / genetics
  • Multiple Myeloma / therapy
  • Neoplasm Recurrence, Local / drug therapy*
  • Pyrazines / administration & dosage
  • Pyrazines / therapeutic use*
  • Retrospective Studies
  • Salvage Therapy
  • Treatment Outcome
  • Young Adult

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Bortezomib
  • Dexamethasone